Among all tumor samples, the overall accordance rates, which combine the results of Gli1-negative and Gli1-positive samples, between Gli1 and BMI1 or SOX2 expression were 85% and 84%, respectively (Table 3). The gene discussed is GLI1; the disease is neoplasm.